Stem cell injection during bypass surgery aims to repair damaged hearts
NCT ID NCT07646210
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-stage study tests a new treatment called HiCM-188, made from stem cells that become heart muscle cells. It is given as a single injection into the heart during bypass surgery in 12 adults with severe heart failure. The main goal is to check safety and see if it improves heart function over 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Texas Heart Institute at Baylor College of Medicine
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Chamber heart pump save the failing heart?
- Can a mechanical heart pump offer a lifeline for advanced heart failure?
- Heart-Kidney link under microscope in advanced heart failure study
- New scan could help decide who benefits from heart surgery
- New heart pump offers hope for advanced heart failure patients
- Rehab program shows promise in tracking blood flow recovery